These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16140010)

  • 1. Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity.
    Lange JH; van Stuivenberg HH; Veerman W; Wals HC; Stork B; Coolen HK; McCreary AC; Adolfs TJ; Kruse CG
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4794-8. PubMed ID: 16140010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
    Lange JH; Coolen HK; van Stuivenberg HH; Dijksman JA; Herremans AH; Ronken E; Keizer HG; Tipker K; McCreary AC; Veerman W; Wals HC; Stork B; Verveer PC; den Hartog AP; de Jong NM; Adolfs TJ; Hoogendoorn J; Kruse CG
    J Med Chem; 2004 Jan; 47(3):627-43. PubMed ID: 14736243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
    Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
    J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
    J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
    Seo HJ; Kim MJ; Lee SH; Lee SH; Jung ME; Kim MS; Ahn K; Kim J; Lee J
    Bioorg Med Chem; 2010 Feb; 18(3):1149-62. PubMed ID: 20045337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentacycle derivatives as cannabinoid CB1 receptor ligands.
    Lee SH; Seo HJ; Kim MJ; Kang SY; Lee SH; Ahn K; Lee M; Han HK; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6632-6. PubMed ID: 19850473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.
    Lange JH; van der Neut MA; den Hartog AP; Wals HC; Hoogendoorn J; van Stuivenberg HH; van Vliet BJ; Kruse CG
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1752-7. PubMed ID: 20137935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
    Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.
    Song KS; Lee SH; Chun HJ; Kim JY; Jung ME; Ahn K; Kim SU; Kim J; Lee J
    Bioorg Med Chem; 2008 Apr; 16(7):4035-51. PubMed ID: 18243711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole.
    Srivastava BK; Soni R; Joharapurkar A; Sairam KV; Patel JZ; Goswami A; Shedage SA; Kar SS; Salunke RP; Gugale SB; Dhawas A; Kadam P; Mishra B; Sadhwani N; Unadkat VB; Mitra P; Jain MR; Patel PR
    Bioorg Med Chem Lett; 2008 Feb; 18(3):963-8. PubMed ID: 18207393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
    Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
    J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.
    Lange JH; Coolen HK; van der Neut MA; Borst AJ; Stork B; Verveer PC; Kruse CG
    J Med Chem; 2010 Feb; 53(3):1338-46. PubMed ID: 20047331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in CB1 cannabinoid receptor antagonists.
    Lange JH; Kruse CG
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):498-506. PubMed ID: 15338959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model.
    Wang H; Duffy RA; Boykow GC; Chackalamannil S; Madison VS
    J Med Chem; 2008 Apr; 51(8):2439-46. PubMed ID: 18363352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
    Brogi S; Corelli F; Di Marzo V; Ligresti A; Mugnaini C; Pasquini S; Tafi A
    Eur J Med Chem; 2011 Feb; 46(2):547-55. PubMed ID: 21183257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists.
    Hou DR; Alam S; Kuan TC; Ramanathan M; Lin TP; Hung MS
    Bioorg Med Chem Lett; 2009 Feb; 19(3):1022-5. PubMed ID: 19095444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
    Rao GK; Kaminski NE
    J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of novel alkenylthiophenes as potent and selective CB1 cannabinoid receptor antagonists.
    Tai CL; Hung MS; Pawar VD; Tseng SL; Song JS; Hsieh WP; Chiu HH; Wu HC; Hsieh MT; Kuo CW; Hsieh CC; Tsao JP; Chao YS; Shia KS
    Org Biomol Chem; 2008 Feb; 6(3):447-50. PubMed ID: 18219411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
    Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
    J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.
    Boström J; Berggren K; Elebring T; Greasley PJ; Wilstermann M
    Bioorg Med Chem; 2007 Jun; 15(12):4077-84. PubMed ID: 17433696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.